SBI MNC Fund
Direct · GrowthAI Summary
SBI MNC Fund has delivered a 1Y SIP XIRR of 17.76%, well above the category average of 14.1%, and its 1Y lump-sum CAGR of 17.86% sharply outpaced the NIFTY 50's -2.9%. Over longer horizons, however, its SIP XIRR of 13.33% (3Y) and 13.17% (5Y) trails the category averages of 16.82% and 16.95% respectively. Against the NIFTY 50, the fund has generated consistent positive alpha across all periods, including 5.93% over 7Y and 5.08% over 15Y.
The fund exhibits a low beta of roughly 0.58-0.62 versus the NIFTY 50 across most windows, with downside capture consistently below upside capture (e.g., 62.94% upside vs 56.41% downside over 5Y), indicating a defensive profile. Risk-adjusted returns are solid, with Calmar ratios above 0.50 across all durations and a modest maximum drawdown of -0.28% lasting 39 days with a 148-day recovery. Seven drawdown events exceeding 10% have occurred historically, so meaningful interim losses are still possible despite the defensive tilt.
The 45-stock portfolio is well diversified at the security level, with the top holding Cummins India at just 5.11% of NAV. Sector-wise, Pharmaceuticals & Biotechnology leads at 20.1%, followed by Auto Components at 14.7% and Chemicals & Petrochemicals at 9.1%, reflecting a consumer-facing, manufacturing-oriented MNC theme. Exposure spans pharma (Divi's, Sun Pharma, Biocon), auto components (Sona Blw, Bosch), and chemicals (Navin Fluorine, Aether), providing reasonable spread within the thematic mandate.
The fund outperforms the category on 1Y SIP XIRR (17.76% vs 14.1%) but lags on 3Y, 5Y, 7Y, 10Y, and 12Y horizons, where category averages run 2.8 to 3.8 percentage points higher. Its lump-sum consistency is stronger, with rolling 12Y mean returns of 15.14% and positive calendar-year alpha versus the NIFTY 50 in most years. This suggests the fund is a steady benchmark-beater but has been a mid-tier performer within the sectoral/thematic category over longer SIP horizons.
This fund suits investors with a high risk tolerance seeking a thematic satellite allocation rather than a core holding, given the concentration risks inherent in sectoral funds. A horizon of at least 5-7 years is advisable to ride out sector cycles, as evidenced by negative calendar-year returns in 2016, 2018, 2022, and 2025. Investors should cap allocation to thematic funds within a broader diversified portfolio and be comfortable with periods of underperformance versus both peers and the broad market.
- Consistent positive alpha versus the NIFTY 50 across all measured periods, including 5.93% over 7Y and 5.08% over 15Y
- Defensive risk profile with beta around 0.60 and downside capture consistently below upside capture
- Strong 1Y performance of 17.76% SIP XIRR, well above the category average of 14.1%
- SIP XIRR trails the category average by roughly 3 percentage points across 3Y, 5Y, 7Y, 10Y, and 12Y horizons
- Thematic concentration in pharma (20.1%) and auto components (14.7%) exposes investors to sector-specific downturns, as seen in negative returns in 2016, 2018, 2022, and 2025
Generated on 06-09-2026, 8:01 PM. Verify before investing.
Gives more importance to longer time periods (10Y, 20Y) than shorter ones (1Y, 3Y). This balances out recent outperformance and gives a more realistic picture of what long-term returns might look like.
The largest peak-to-trough decline in the fund's NAV. Shows the worst-case loss an investor would have experienced at any point in the fund's history.
If you invested ₹1,00,000 every month via SIP, here's how this fund has historically performed across different time horizons.
| Duration | Invested | Median Value | XIRR | Min XIRR | Max XIRR |
|---|---|---|---|---|---|
| 1 Year | ₹12.00 L | ₹12.70 L | 17.8% | -38.6% | 102.2% |
| 3 Years | ₹36.00 L | ₹43.20 L | 13.3% | -12.8% | 33.5% |
| 5 Years | ₹60.00 L | ₹84.63 L | 13.2% | -3.8% | 24.7% |
| 7 Years | ₹84.00 L | ₹1.35 Cr | 13.5% | 3.6% | 18.1% |
| 10 Years | ₹1.20 Cr | ₹2.44 Cr | 13.3% | 9.2% | 16.0% |
| 12 Years | ₹1.44 Cr | ₹3.11 Cr | 12.4% | 9.8% | 15.5% |
SIP returns vs benchmark & category
Annualised SIP return (XIRR) over each rolling horizon — like-for-like, not lump-sum.
| Duration | Fund SIP XIRR | NIFTY 50 | Category avg | Fund edge |
|---|---|---|---|---|
| 1 Year | 17.8% | 14.4% | 14.1% | +3.4% |
| 3 Years | 13.3% | 11.1% | 16.8% | +2.2% |
| 5 Years | 13.2% | 10.4% | 16.9% | +2.8% |
| 7 Years | 13.5% | 10.6% | 16.5% | +2.9% |
| 10 Years | 13.3% | 11.5% | 16.7% | +1.9% |
| 12 Years | 12.4% | 11.4% | 16.3% | +1.1% |
| Duration | Mean | Median | Min | Max | Sharpe | Sortino | % Positive | Cat. Mean | Cat. Median |
|---|---|---|---|---|---|---|---|---|---|
| 1 Year | 16.9% | 12.0% | -18.7% | 86.0% | 0.50 | 2.01 | 82% | — | — |
| 3 Years | 14.4% | 13.0% | -0.8% | 34.7% | 1.12 | 11.75 | 100% | — | — |
| 5 Years | 14.2% | 14.4% | 1.1% | 25.7% | 1.71 | 18.43 | 100% | — | — |
| 10 Years | 14.1% | 13.4% | 9.8% | 19.8% | 2.70 | — | 100% | — | — |
Calmar Ratio by Duration
Compared against NIFTY 50
| Duration | Alpha | Beta | Upside Capture | Downside Capture | Fund CAGR | Bench CAGR |
|---|---|---|---|---|---|---|
| 1 Year | +18.91 | 0.80 | 86.7% | 61.1% | 17.9% | -2.9% |
| 3 Years | +2.05 | 0.62 | 65.8% | 60.0% | 9.3% | 7.8% |
| 5 Years | +2.64 | 0.61 | 62.9% | 56.4% | 9.9% | 7.8% |
| 7 Years | +5.93 | 0.58 | 61.2% | 52.2% | 15.5% | 11.8% |
| 10 Years | +3.18 | 0.60 | 62.9% | 56.4% | 12.3% | 10.8% |
| 12 Years | +4.79 | 0.60 | 63.7% | 55.5% | 13.3% | 9.8% |
| 15 Years | +5.08 | 0.58 | 62.8% | 53.5% | 13.5% | 9.7% |
| # | Stock | % of NAV |
|---|---|---|
| 1 | Cummins India Ltd. | 5.11% |
| 2 | Divi's Laboratories Ltd. | 4.97% |
| 3 | Vedanta Aluminium Metal Ltd. | 4.20% |
| 4 | Sun Pharmaceutical Industries Ltd. | 3.69% |
| 5 | Sona Blw Precision Forgings Ltd. | 3.56% |
| 6 | Maruti Suzuki India Ltd. | 3.29% |
| 7 | Navin Fluorine International Ltd. | 3.27% |
| 8 | Aether Industries Ltd. | 3.23% |
| 9 | Bosch Ltd. | 3.17% |
| 10 | Biocon Ltd. | 2.96% |